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of risk factors, and smoking status. Patients with ≥4 risk factors account for 71.7% 
of current glycemic control group, while this value reached 84.3% in the uncontrolled 
group (P < 0.0001). CONCLUSIONS: In one out of seven patients with DM2 and 
poor glycemic control, none action to intensify treatment has been taken during the 
past 2 years. Patients without current glycemic control have more than two times 
higher clinical inertia than the controlled ones. Intensiﬁ cation of treatment is twice as 
common in patients currently uncontrolled (85.1% vs. 44.9%).
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OBJECTIVES: Diabetes affects approximately 8 million people in Mexico and is the 
ﬁ rst cause of death in the country. Ninety percent of all diabetes is classiﬁ ed as type 
II diabetes (T2DM). Saxagliptin, a DPP4 inhibitor, is one of a class of drugs orally 
administered for treatment of T2DM. Petroleos Mexicanos (PEMEX) health-care 
system covers approximately 43,977 patients diagnosed with T2DM. The objectives 
of this study are to: 1) analyze the current utilization and expenditure for oral antidia-
betics (OADs) by PEMEX; and 2) evaluate the budget impact of saxagliptin for 
treatment of T2DM population. METHODS: An MS Excel-based budget impact 
model of the total population diagnosed with T2DM in PEMEX was used. OAD usage 
was based on the total amount purchased, by the Institution in 2009. The prices of 
medications were taken from the published price listing by PEMEX (2009). The fol-
lowing OAD medications were included in the analysis: pioglitazone, rosiglitazone, 
vildagliptin, and saxagliptin. Pharmaceutical expenses of OADs were considered 
excluding other medical costs. The time horizon was 3 years and the assumptions of 
the model including market dynamics were estimated by Bristol Myers Squibb. The 
budget impact is reported in terms of additional annual total costs. Results are pre-
sented in US dollars with an exchange rate of $13.4 MXN. RESULTS: The usage of 
saxagliptin in PEMEX represents savings to the institution of US$56,132 for the ﬁ rst 
year of use, with increases in savings for year two and year three US$102,910 and 
US$154,441 respectively. The impact of saxagliption on the budget was primarily 
driven by the gradual substitution of pioglitazone, rosiglitazone, and vildagliptin with 
saxagliptin over the 3-year of analysis. CONCLUSIONS: The budget impact of adding 
saxagliptin as a treatment option for T2DM patients reveals that the accumulated 
savings for PEMEX for the estimated timeframe is around US$ 313,485.
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OBJECTIVES: The present model was aimed to demonstrate the annual cost of the 
smoking-related diseases in patients with type 2 diabetes mellitus (DM) and chronic 
obstructive pulmonary disease (COPD), and to establish the budget that would be 
saved with varenicline (nicotinic receptor partial agonist) reimbursement by the gov-
ernment. METHODS: The model was carried out in two contexts; the costs of the 
smoking-related diseases and exacerbations in patients with type 2 DM and COPD 
were estimated in smoking conditions, and varenicline use. The model was constructed 
on a total of 900,000 type 2 DM patients and 106,410 COPD patients by assuming 
approximately 3.8 million type 2 DM patients and 2.0 million COPD patients in 
Turkey of which 23% and 48% were considered to be smokers, respectively. 
RESULTS: According to the model, the ratio of patients willing to quit smoking was 
estimated as 35% in type 2 DM group and 54% in COPD group. Of those, 20% (n 
= 63,000) type 2 DM patients and 30% (n = 17,238) COPD patients were assessed 
to use varenicline. The annual cost of the smoking-related diseases and exacerbations 
was calculated as 72.40 million USD according to the 43,341 events; the unit direct 
costs for myocardial infarcts, stroke, and congestive heart failure were calculated as 
US$2,523.55, US$1,930.70, and US$1,412.33, respectively, in type 2 DM patients, 
whereas it was US$1,567.55 in COPD patients. After varenicline use, the government 
would save US$9.47 million per year by 5608 preventable events. Moreover, the 
annual cost of varenicline was estimated to be US$23.46 million for 80,238 patients. 
Accordingly, the total cost of the smoking-related diseases and exacerbations would 
be US$13.99 million for the ﬁ rst year. CONCLUSIONS: Varenicline reimbursement 
decreases the annual cost of the smoking-related diseases and exacerbations in patients 
with type 2 DM and COPD.
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OBJECTIVES: Large published data suggested that some patients initiating with the 
recommended once-daily detemir administration require twice-daily dosing to opti-
mize blood glucose control; therefore, the clinical outcome in this selected population 
was tested in a randomized controlled trial. The objective of this study is to compare 
the costs of two treatments of type 2 diabetes mellitus (DM2): Insulin glargine 
(glargine) and insulin detemir (detemir) in patients with DM2 not controlled with 
OADs. METHODS: A costs analysis of the insulin treatment was carried out with 
National Health System perspective. Costs with glargine or detemir linked to DM2 
patients were calculated according to the administered doses in a clinical trial of 24 
weeks of duration, which included 964 insulin-naive patients, with a DM2 average 
duration of 10 years and average HbA1c = 8.7%. For both insulin, started dose was 
0, 2 U/kg. The administration of a daily dose of glargine and two daily doses of 
detemir led to similar average levels of glycosylated hemoglobin (−1.46 ± 1.09 and 
−1.54 ± 1.11 %; P = 0.149). However, patients treated with glargine needed signiﬁ -
cantly minor insulin than those treated with detemir (43.5 vs. 76.5 U, P < 0.001). 
RESULTS: The application of this model would be translated in minor daily costs for 
glargine and concretely its use would suppose an annual cost of c814.52 opposite to 
the c1461.5 of detemir. In consequence, utilization of glargine instead of detemir 
would be associated with an annual saving of c647.13 for patient with DM2, which 
supposes a saving of 44.2% with glargine opposite to detemir. CONCLUSIONS: 
According to the present model, in the above mentioned population, insulin glargine 
is a treatment of the DM2 associated with minor costs than insulin detemir.
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OBJECTIVES: The objective of this study is to determine the potential differences in 
the economical impact for the National Health System (NHS) in Spain of using dif-
ferent glucometric systems for self-monitoring blood glucose (SMBG) in patients with 
type II diabetes mellitus (DM II). METHODS: An economic model was built based 
on three information sources: 1) literature review; 2) costs databases; and 3) expert 
opinion. Six different glucometers were analyzed according to their codiﬁ cation char-
acteristics and their corresponding strips package characteristics, leading to four dif-
ferent system possibilities: 1) autocoded/individual strip package; 2) manually coded/
individual strip package; and 3) autocoded/ collective strip package; and 4) manually 
coded/collective strip package. The perspective was that of the NHS. RESULTS: With 
more than 2 million people suffering from DM II in Spain, we calculated the impact 
of glucometer miscoding relating it to cardiovascular episodes and glucose disorders 
occurred. Also, collective strip package implied, due to shorter time of strip stability 
after its opening, considerable strip waste especially in those patients with low fre-
quency of SMBG recommendation. Results show that autocoded glucometers which 
have individual package for strips safe c5 million (10%) versus those manually coded 
and having individual strip package in diabetic patients’ management to the NHS; 
versus those autocoded but with collective strip package, savings rise to c15 million 
(24%) and versus those manually coded and with collective package the amount of 
saving is of c22 million (31%). The one-way sensitivity analysis performed with the 
most relevant variables conﬁ rmed this tendency. CONCLUSIONS: Glucometric 
systems not requiring patient intervention for coding and with individual strip package 
minimize the total cost of SMBG of type II diabetic patients in Spain.
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OBJECTIVES: Despite the efforts made worldwide, data regarding the cost of care in 
Pakistan are scarce. This study was aimed at assessing the direct costs incurred in the 
treatment of diabetes and its variation among government, semi-government, and 
private sectors of Islamabad, Pakistan. METHODS: It was a comparative cross-sec-
tional study in which data was collected from patients by conveniently sampling. The 
direct cost of treatment of diabetes was determined in terms of variables consultation 
fee, cost of medicine, travelling cost, fees for laboratory test for glucose monitoring, 
cost of home blood glucose monitoring device, and cost of strips used for home blood 
glucose monitoring. RESULTS: The annual mean direct cost for government, semi-
government, and private sectors were Rs. 6481.73, Rs. 9785.25 and Rs. 27790.31, 
respectively, while the monthly mean directs costs were Rs. 540.14, Rs. 815.43, and 
Rs. 2315.85, respectively. The total direct cost of treatment of diabetes per month for 
all health facilities was Rs. 986.61. It was found from the analysis that the mean costs 
for individual variables were highest in the private sector as compared to semi-gov-
ernment and government sector. The consultation fee charged by the private sector is 
much higher than the other two sectors. CONCLUSIONS: The private sector of Paki-
stan is incurring more cost for the treatment of diabetes mellitus. This difference in 
cost among health sectors is a burden on the economic status of the country. More-
over, untreated diabetes or comorbidities increase the overall treatment cost and this 
can affect the affordability of the patient.
